EGFR and non-small cell lung carcinoma: The novelty of these findings resides in having identified that MUC1-C is (i) an effector of a NSCLC STAT1-mediated inflammatory memory pathway that drives resistance to EGFR-TKIs and (ii) a target with an M1C ADC for the treatment of TKI-refractory NSCLC tumors.